On June 13, 2016 Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) reported that data from its 1404 and PyLTM prostate cancer imaging programs will be presented at the upcoming Society of Nuclear Medicine and Molecular Imaging 2016 Annual Meeting, taking place from June 11 — 15, 2016 in San Diego, California (Press release, Progenics Pharmaceuticals, JUN 13, 2016, View Source [SID:1234513241]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The details of the presentations are included below.
1404 Tc-99m Diagnostic Imaging Agent
Title: SPECT/CT Imaging of Prostatic PSMA Expression with Tc99m trofolastat chloride in Healthy Volunteers
Date and Time: June 13th from 3:00 — 4:30 p.m. PT
Poster Number: 1546
Session: Meet the Author Poster Session I: Prostate/GU Posters
PyL F-18 Diagnostic Imaging Agent
Title: Normal Organ Uptake Variability on PSMA-Targeted 18F-DCFPyL PET/CT
Date and Time: June 14th at 4:54 p.m. PT
Poster Number: 519
Session: SS76: Prostate/GU: Prostate and Other Malignancies
Title: Application of 18F-labeled PSMA-imaging using [18F]DCFPyL at very low PSA-values may allow curative treatment in recurrent prostate cancer
Date and Time: June 15th at 8:24 a.m. PT
Poster Number: 561
Session: SS82: Prostate/GU: PSMA Imaging in Advanced Disease
About 1404, an Imaging Compound Targeting Prostate Specific Membrane Antigen
Progenics’ molecular imaging radiopharmaceutical product candidate 1404 targets the extracellular domain of prostate specific membrane antigen (PSMA), a protein amplified on the surface of >95% of prostate cancer cells and a validated target for the detection of primary and metastatic prostate cancer. 1404 is labeled with technetium-99m, a gamma-emitting isotope that is widely available, is easy to prepare, and is attractive for nuclear medicine imaging applications. The image created provides the opportunity to visualize cancer, potentially allowing for improved detection and staging, more precise biopsies, and a targeted treatment plan including active surveillance as a disease management tool.
About PyL for PET Imaging of Prostate Cancer
PyL (also known as [18F]DCFPyL) is a clinical-stage, fluorinated PSMA-targeted PET imaging agent for prostate cancer that was discovered and developed at the Center for Translational Molecular Imaging at the Johns Hopkins University School of Medicine. A proof-of-concept study published in the April 2015 issue of the Journal of Molecular Imaging and Biology demonstrated that PET imaging with PyL showed high levels of PyL uptake in sites of putative metastatic disease and primary tumors, suggesting the potential for high sensitivity and specificity in detecting prostate cancer.
About Prostate Cancer
Prostate cancer is the second most common form of cancer affecting men in the United States: an estimated one in seven men will be diagnosed with prostate cancer in his lifetime. The American Cancer Society estimates that approximately 180,890 new cases of prostate cancer will be diagnosed and about 26,120 men will die of the disease and that approximately 2.9 million men in the U.S. currently count themselves among prostate cancer survivors.